Cilnidipine

Summary

Cilnidipine (CHEMBL452076) is a phase-3 clinical-stage small-molecule calcium channel blocker (ATC C08CA14) targeting CACNA1B; indicated across 3 conditions including cardiovascular disorder and hypertensive disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: C08CA14
• Targets: 1 (CACNA1B)
• Indications: 3 conditions
• Clinical trials: 5
• Chemistry: 492.5 Da · C27H28N2O7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL452076
Name	Cilnidipine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	5282138
ChEBI	CHEBI:31399
ATC	C08CA14
Molecular formula	C27H28N2O7
Molecular weight	492.5
InChIKey	KJEBULYHNRNJTE-DHZHZOJOSA-N

SMILES: CC1=C(C(C(=C(N1)C)C(=O)OC/C=C/C2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OCCOC

IUPAC name: 3-O-(2-methoxyethyl) 5-O-[(E)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

ChEBI definition: A diesterified 1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium channel blocker, it is used as an antihypertensive.

Pharmacological roles (ChEBI): calcium channel blocker, antihypertensive agent, cardiovascular drug.

Also known as: Atelec, Cilnidipine, Cilnidipino, Cinalong, FRC-8653, Siscard, SID26755677, SID50111041, SID90341030, Clinidipine, SID144205554, SID170465867

Patent coverage: 1,417 distinct patent families (5,373 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 5,339 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CACNA1B	Cav2.2	Pore blocker	6.7	0.3%	Q00975

Broader ChEMBL bioactivity targets: 15 (assay-derived). Sample: Nuclear receptor ROR-gamma, Ferritin light chain, Voltage-dependent T-type calcium channel subunit alpha-1H, Voltage-dependent L-type calcium channel subunit alpha-1C, Equilibrative nucleoside transporter 1, Glucocorticoid receptor, Thromboxane A2 receptor, Menin/Histone-lysine N-methyltransferase MLL, Voltage-gated L-type calcium channel, Motilin receptor, Adenosine receptor A3, 3’,5’-cyclic-AMP phosphodiesterase 4D, Nuclear receptor subfamily 1 group I member 2, Voltage-dependent N-type calcium channel subunit alpha-1B, Huntingtin.

Bioactivity

ChEMBL activities: 11 potent at pChembl ≥ 5 of 24 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P22002	8.96	IC50	1.1	nM	CHEMBL_ACT_1678941
P22002	8.96	IC50	1.1	nM	CHEMBL_ACT_2233361
P22002	8.96	IC50	1.1	nM	CHEMBL_ACT_6208004
NR1I2	6.11	AC50	780	nM	CHEMBL_ACT_25224368
CACNA1B	5.8	IC50	1600	nM	CHEMBL_ACT_1678936
MEN1	5.75	Potency	1778	nM	CHEMBL_ACT_4573879
ADORA3	5.32	AC50	4800	nM	CHEMBL_ACT_25134268
CACNA1C	5.28	IC50	5300	nM	CHEMBL_ACT_15373213
NR3C1	5.19	AC50	6500	nM	CHEMBL_ACT_25175900
PDE4D	5.09	AC50	8200	nM	CHEMBL_ACT_25185384
MEN1	5	Potency	10000	nM	CHEMBL_ACT_4559406

Target pathways

Aggregated over 1 target gene(s): CACNA1B.

Top Reactome pathways

3 total, by targets touching each:

Pathway	Targets	Genes
Presynaptic depolarization and calcium channel opening	1	CACNA1B
Transmission across Chemical Synapses	1	CACNA1B
Neuronal System	1	CACNA1B

Dominant GO biological processes

GO term	Targets
chemical synaptic transmission	1
modulation of chemical synaptic transmission	1
calcium ion import across plasma membrane	1
positive regulation of calcium ion-dependent exocytosis of neurotransmitter	1
response to amyloid-beta	1
monoatomic ion transport	1
calcium ion transport	1
monoatomic ion transmembrane transport	1
transmembrane transport	1
calcium ion transmembrane transport	1

Indications & clinical

Indications

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
cardiovascular disorder	3	MONDO:0004995	EFO:0000319
hypertensive disorder	3	MONDO:0005044	EFO:0000537
autosomal dominant polycystic kidney disease	2	MONDO:0004691	EFO:1001496

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE4	2
PHASE3	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00325936	PHASE4	COMPLETED	The Effects of Cilnidipine on Metabolic Syndrome Improvement
NCT00541853	PHASE4	UNKNOWN	CCB Safety Study in Treatment of Hypertension of ADPKD
NCT00325637	PHASE3	COMPLETED	Cilnidipine Effect on High Blood Pressure and Cerebral Perfusion in Ischemic Stroke Patients With Hypertension
NCT00890279	PHASE2	UNKNOWN	Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)
NCT02343250	PHASE1	COMPLETED	A Bioequivalence Study Comparing Cilnidipine/Valsartan Combination With Coadministration of Cilnidipine and Valsartan

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

25 molecules share ≥1 primary target. Top 25 by shared-target count:

Molecule	Source	Status	Shared targets
AMITRIPTYLINE	ChEMBL + PubChem	Phase 4 (approved)	CACNA1B
AMOXAPINE	ChEMBL + PubChem	Phase 4 (approved)	CACNA1B
CLOMIPRAMINE	ChEMBL + PubChem	Phase 4 (approved)	CACNA1B
CYCLOBENZAPRINE	ChEMBL + PubChem	Phase 4 (approved)	CACNA1B
DESIPRAMINE	ChEMBL + PubChem	Phase 4 (approved)	CACNA1B
IMIPRAMINE	ChEMBL + PubChem	Phase 4 (approved)	CACNA1B
ZICONOTIDE	ChEMBL + PubChem	Phase 4 (approved)	CACNA1B
MAPROTILINE	ChEMBL	Phase 4 (approved)	CACNA1B
MIBEFRADIL	ChEMBL	Phase 4 (approved)	CACNA1B
NIFEDIPINE	ChEMBL	Phase 4 (approved)	CACNA1B
NIMODIPINE	ChEMBL	Phase 4 (approved)	CACNA1B
NORTRIPTYLINE	ChEMBL	Phase 4 (approved)	CACNA1B
PROMETHAZINE	ChEMBL	Phase 4 (approved)	CACNA1B
PROTRIPTYLINE	ChEMBL	Phase 4 (approved)	CACNA1B
TACRINE	ChEMBL	Phase 4 (approved)	CACNA1B
TRIMIPRAMINE	ChEMBL	Phase 4 (approved)	CACNA1B
HESPERIDIN	ChEMBL	Phase 3	CACNA1B
OPIPRAMOL	ChEMBL	Phase 3	CACNA1B
FLUNARIZINE	ChEMBL	Phase 2	CACNA1B
LOMERIZINE	ChEMBL	Phase 2	CACNA1B
SELICICLIB	ChEMBL	Phase 2	CACNA1B
Z160	ChEMBL	Phase 2	CACNA1B
Clotrimazole	PubChem	Approved	CACNA1B
Econazole	PubChem	Approved	CACNA1B
Miconazole	PubChem	Approved	CACNA1B